Treatment Group 3 for Liver Cirrhosis (ZEAL UNLOCK Trial)

"Indeed, information from clinicaltrials.gov shows that this research is actively seeking participants. It was initially posted on February 15th, 2024 and most recently updated on March 22nd, 2024. The study aims to enroll a total of 66 patients distributed among 41 different sites."

"This clinical trial aims to enroll 66 individuals aged between 18 and 80 with a current diagnosis of liver cirrhosis. In order to be eligible, patients must not have experienced any deterioration in hepatic function within the month leading up to dosing, as confirmed by the investigator or regular healthcare provider. They should also not have received treatment with an SGLT2 inhibitor or endothelin receptor antagonist within a month before enrollment. Additionally, participants must exhibit signs of compensated cirrhosis with features of CSPH (such as varices observed during endoscopy), elevated liver stiffness (>25 kPa or >21 kPa) alongside"

"Indeed, the information available on clinicaltrials.gov indicates that this research project is actively searching for eligible participants. The trial was first listed on February 15th, 2024 and last revised on March 22nd, 2024. A total of 66 individuals are sought from a network of 41 sites."

"At present, 41 medical facilities are enrolling participants for this study. The trial sites can be found in various places such as Yokohama-shi, Plzeň, and Milano among other locations worldwide. Opting for the site nearest to your location is advisable to reduce travel requirements during your participation."

"Participants between the ages of 18 and up to 80 years old are eligible for enrollment based on the trial's inclusion criteria."

"According to Power's assessment, the safety rating for Treatment Group 3 is a moderate 2 on a scale of 1 to 3. This evaluation is based on Phase 2 trial data that indicates some evidence supporting safety but lacks efficacy data."